Catalog # 10-4564
NLG919

CAS# 1402836-58-1

1-Cyclohexyl-2-(5H-imidazo[5,1-a]isoindol-5-yl)ethanol

Lot # FBS2001



NLG919 (1402836-58-1) is a potent IDO-pathway inhibitor (Ki = 7nM; EC_{50} = 75nM).[1] It synergizes with chemo-radiation therapy to promote T cell dependent complement deposition in a murine model of glioblastoma.[2] In combination with paclitaxel in a mouse B16-F10 melanoma model, NLG919 increased the percentage of $CD3^+$, $CD8^+$, and $CD4^+$ T cells and secretion of IFN-γ and interleukin-2 while decreasing the percentage of $CD4^+CD25^+$ regulatory T cells.[3]

1) Mautino *et al.* (2013), *NLG919, a novel indolamine-2,3-dioxygenase (IDO)-pathway inhibitor drug candidate for cancer therapy;* Cancer Res. **73** issue 8 supplement 491
2)) Li *et al.* (2014), *The indolamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma;* J. Immunother. Cancer **2** 21
3) Meng *et al.* (2017), *Combinatorial antitumor effects of indoleamine 2,3-dioxygenase inhibitor NLG919 and paclitaxel in a murine B16-F10 melanoma model;* Int. J. Immunopathol. Pharmacol. **30** 215

PHYSICAL DATA

Molecular Weight:	282.39
Molecular Formula:	$C_{18}H_{22}N_2O$
Purity:	>98% by HPLC
	NMR: (Conforms)
Solubility:	DMSO (15 mg/ml)
Physical Description:	White solid
Storage and Stability:	Store as supplied at -20ºC for up to 1 year from the date of purchase. Solutions in DMSO may be stored at -20°C for up to 1 month.

Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications.

Focus Biomolecules LLC 400 Davis Drive, Suite 600 Plymouth Meeting PA 19462

www.focusbiomolecules.com